Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate.

Yang KH, Park SY, Park SW, Lee SH, Han SB, Jung WK, Kim SJ.

J Bone Miner Metab. 2010 Nov;28(6):713-8. doi: 10.1007/s00774-010-0203-2. Epub 2010 Jul 6.

PMID:
20607326
2.

Altered bone and mineral metabolism in patients receiving imatinib mesylate.

Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP.

N Engl J Med. 2006 May 11;354(19):2006-13.

3.

Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.

Jönsson S, Standal T, Olsson B, Mellström D, Wadenvik H.

Am J Hematol. 2012 May;87(5):550-2. doi: 10.1002/ajh.23155. Epub 2012 Mar 9.

4.

Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.

Ianotto JC, Tempescul A, Amet Y, Grall P, Dalbies F, Eveillard JR, Guillerm G, Berthou C.

Am J Hematol. 2012 Apr;87(4):437-9. doi: 10.1002/ajh.23113. Epub 2012 Jan 28. No abstract available.

5.

Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.

Grey A, O'Sullivan S, Reid IR, Browett P.

N Engl J Med. 2006 Dec 7;355(23):2494-5. No abstract available.

6.

Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.

Jaeger BA, Tauer JT, Ulmer A, Kuhlisch E, Roth HJ, Suttorp M.

Med Sci Monit. 2012 Dec;18(12):CR721-8.

7.

[Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].

Voglová J, Poznarová A, Chrobák L, Rabasová J, Beránek M, Moravcová J, Faber E, Klamová H, Cikhart M.

Vnitr Lek. 2004 Jan;50(1):21-3, 26-9. Czech.

PMID:
15015226
9.

Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.

Campione E, Diluvio L, Paternò EJ, Di Marcantonio D, Francesconi A, Terrinoni A, Orlandi A, Chimenti S.

Clin Ther. 2009 Nov;31(11):2565-9. doi: 10.1016/j.clinthera.2009.11.018.

PMID:
20110001
10.

Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.

Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino AC.

J Clin Endocrinol Metab. 2013 Jan;98(1):67-76. doi: 10.1210/jc.2012-2426. Epub 2012 Nov 8.

PMID:
23144472
11.

Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.

O'Sullivan S, Horne A, Wattie D, Porteous F, Callon K, Gamble G, Ebeling P, Browett P, Grey A.

J Clin Endocrinol Metab. 2009 Apr;94(4):1131-6. doi: 10.1210/jc.2008-2324. Epub 2009 Jan 27.

PMID:
19174494
12.

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.

Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Medeiros LJ, Kantarjian H.

Cancer. 2004 Jul 15;101(2):332-6.

13.

Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.

Patel VC, Lazzarini AM.

Orthopedics. 2010 Oct 11;33(10):775. doi: 10.3928/01477447-20100826-31.

PMID:
20954650
14.
15.

Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.

Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G.

Arch Dermatol. 2005 Mar;141(3):368-70.

PMID:
15781678
16.

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J.

Blood. 2006 Sep 15;108(6):1835-40. Epub 2006 May 18.

17.

Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.

McNamara C, Grigg A, Szer J, Roberts A, Campbell L, Hoyt R, Lynch K, Juneja S.

Clin Lab Haematol. 2003 Apr;25(2):119-25.

PMID:
12641616
18.

Pathological fracture as a manifestation of extramedullary blastic crisis in chronic myelogenous leukemia: report of one case.

Yu HH, Lu MY, Lin DT, Lin KH, Tang JL, Jou ST.

Acta Paediatr Taiwan. 2006 May-Jun;47(3):150-4.

PMID:
17078470
19.

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.

Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.

Cancer. 2003 Dec 15;98(12):2636-42.

20.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk